Skip to main content
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. — Investor Relations & Filings

Ticker · ANTX ISIN · US0373261058 US Manufacturing
Open in API
Filings indexed 339 across all filing types
Latest filing 2023-06-10 Director's Dealing
Country US United States of America
Listing US ANTX

About AN2 Therapeutics, Inc.

https://www.an2therapeutics.com/

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing treatments for rare, chronic, and serious infectious diseases with high unmet medical needs. The company utilizes its proprietary boron chemistry platform to create novel small molecule therapeutics. Its development pipeline includes boron-based compounds, such as its lead candidate epetraborole, which are being investigated as potential first-in-class or best-in-class therapies. The company's mission is to deliver high-impact drugs to improve global health outcomes, with potential applications extending to oncology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-06-10 English
FORM 4 SUBMISSION
Director's Dealing
2023-06-10 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 7, 2023, reporting the submission of matters to a vote of security holders at the company's 2023 annual meeting. It includes detailed certified voting results for director elections and ratification of the independent auditor. The content focuses on official voting results from the annual meeting, which matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4285 characters, which is relatively short but contains the full voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA). The document is not a full annual report, proxy statement, or management discussion, but specifically the voting results. Hence, the correct classification is DVA with high confidence.
2023-06-09 English
FORM 4 SUBMISSION
Director's Dealing
2023-05-16 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2023, reporting the issuance of a press release announcing financial results for the first quarter ended March 31, 2023. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference, indicating this document is a current report announcing financial results rather than the full earnings release itself. The document length is 3482 characters, which is relatively short and consistent with an 8-K filing that includes a press release. The key section is Item 2.02 "Results of Operations and Financial Condition," which typically corresponds to an earnings release announcement. Therefore, this document is best classified as an Earnings Release (ER) filing, as it announces quarterly financial results.
2023-05-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.